Tscan Therapeutics Inc
NASDAQ:TCRX 3:59:51 PM EDT
Earnings Announcements
Tscan Therapeutics Reports First Quarter 2022 Financial Results
Published: 05/09/2022 13:46 GMT
Tscan Therapeutics Inc (TCRX) - Tscan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones.
Q1 Revenue $3.0 Million.
Ended Q1 With Cash and Cash Equivalents of $140.8 Million, Funding Operations Into 2024.
Qtrly Loss per Share $0.67.
Q1 Earnings per Share View $-0.73 -- Refinitiv Ibes Data (analyst estimates).
Q1 Revenue $3.0 Million.
Ended Q1 With Cash and Cash Equivalents of $140.8 Million, Funding Operations Into 2024.
Qtrly Loss per Share $0.67.
Q1 Earnings per Share View $-0.73 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3 Million
Adjusted EPS is expected to be -$0.74
Next Quarter Revenue Guidance is expected to be $3.66 Million
Next Quarter EPS Guidance is expected to be -$0.74
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.74
Next Quarter Revenue Guidance is expected to be $3.66 Million
Next Quarter EPS Guidance is expected to be -$0.74
More details on our Analysts Page.